Olanzapine long-acting injection: A 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia

American Journal of Psychiatry

Volumn 167, Issue 2, 2010, Pages 181-189

  Kane, John M ^a   Detke, Holland C ^a   Naber, Dieter ^a   Sethuraman, Gopalan ^a   Lin, Daniel Y ^a   Bergstrom, Richard F ^a   McDonnell, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; LONG ACTING DRUG; LORAZEPAM; OLANZAPINE;

ACUTE PSYCHOSIS; ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE EXACERBATION; DISEASE FREE INTERVAL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INCIDENCE; INJECTION; INJECTION SITE REACTION; INSOMNIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALAISE; MALE; ONSET AGE; OUTPATIENT; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; STEADY STATE; SUICIDAL IDEATION; TREATMENT DURATION; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; YOUNG ADULT;

EID: 75749098515     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2009.07081221     Document Type: Article

References (17)

1. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56:241-247
2. Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC: Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 2006; 67:1542-1550
3. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E: Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979; 36:1283-1294
4. Kane JM: Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 2006; 67(suppl 5):9-14
5. Schooler NR: Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003; 64(suppl 16):14-17
6. Patel MX, de Zoysa N, Vernadt M, David AS: A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral. J Clin Psychiatry 2008; 69:1548-1556
7. Zypadhera European Public Assessment Report: Annex I Summary of Product Characteristics. http://www.emea.europa.eu/humandocs/Humans/EPAR/zypadhera/ zypadhera.htm. (Accessed March 25, 2009)
8. Guy W: Early Clinical Drug Evaluation Unit Assessment Manual for Psychopharmacology-Revised (Publication ADM 76-338). Bethesda, Md, United States Department of Health, Education, and Welfare, 1976
9. Kay S, Opler L, Fiszbein A: Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY, Multi-Health Systems, 1986
10. National Cholesterol Education Program: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002; 106:3143-3421
11. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 2004; 27(suppl 1):S15-S35
12. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
13. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212:S11-S19
14. Beasley CM Jr, Sutton VK, Hamilton SH, Walker DJ, Dossenbach M, Taylor CC, Alaka KJ, Bykowski D, Tollefson GD: A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003; 23:582-594
15. Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr: Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997; 48:1571-1577
16. Bergstrom R, Callahan J, Cerimele J, Kurtz D, Hatcher B: Population pharmacokinetics and plasma concentrations of olanzapine, in Olanzapine (Zyprexa): A Novel Antipsychotic. Edited by Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G. Philadelphia, Lippincott, Williams and Wilkins, 2000
17. Downham TF, Cawley RA, Salley SO, Dal Santo G: Systemic toxic reactions to procaine penicillin G. Sex Transm Dis 1978; 5:4-9